43. The method of claim 39 wherein the administration of an effective amount of uridine or its precursor does not include the administration of cytidine.

~~44.~~ The method of claim 39 wherein an effective amount of uridine or its precursor is administered at least once a day.

45. The method according to claim 42 wherein said memory disorder is associated with aging.

46. The method of claim 39 which further comprises administering a therapeutically effective dose of a second compound.

47. The method according to claim 46 wherein said second compound is choline, a choline salt, CDP-choline, lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, glycerophosphatidylcholine, or mixtures thereof.

48. The method according to claim 47 wherein said choline salt is selected from the group consisting of choline chloride, choline bitartrate, choline stearate, or mixtures thereof.

49. The method of claim 46 ~~wherein said second compound is a uridine phosphorylase~~ inhibitor, uridine ~~secretion~~ inhibiting compound, uridine renal transport competitor, or combinations ~~thereof~~.

50. A method of increasing brain cytidine levels in a human suffering from a memory disorder comprising administering an effective amount of a composition comprising uridine or a precursor thereof.--

REMARKS

Claims 1-38 are pending in this application. Claims 1-38 are canceled. Claims 39-50 are added for examination in this application.

Support for claims 39-49 can be found in the specification at page 6 line 15 et seq., page 10 line 8 et seq., Example 2, Example 3, and elsewhere. Moreover, additional support for claim 46 is found on page 10 line 10 et seq. The agents of claim 47 are found in the specification on page 10 line 20, and on page 15 line 5 et seq. The salts of choline, as recited in claim 48, are found on page 10 line 20 et seq. Support for claim 50 is found in Example 3 and elsewhere. No new matter has been added.